Amsterdam, 15 November 2022 – Teledyne DALSA, a Teledyne Technologies company and global leader in Digital X-Ray Image Sensing technology, is pleased to announce it has acquired the Sigmascreening B.V. patents and IP portfolio on pressure-sensitive breast compression for screening. With its purchase, Teledyne DALSA has exclusive access to the Sigmascreening IP portfolio and algorithms. Holland Capital was one of the early investors in Sigmascreening.
Unique combination
The unique combination of detector and pressure-sensitive compression is expected to create new possibilities for immediate diagnostic information as well as biomarkers for breast screening. According to Thorsten Achterkirchen, Vice President and General Manager of Teledyne DALSA’s X-Ray Solutions business, “We intend to expand our CMOS X-Ray detector product line for mammography and digital breast tomosynthesis (DBT) with new subsystem products for optimizing breast imaging and improving patient comfort during mammographic screening.”
Ivo Aarninkhof, CEO of Sigmascreening, says that ‘’We are delighted with the purchase of the Sigmascreening patents and IP portfolio by Teledyne DALSA. Use of the pressure-based compression during digital breast tomosynthesis and mammography improves participant and technologist experience and reduces compression pressure variability, mean breast thickness, and glandular dose.”1
Expertise in radiology
Holland Capital joined the company in 2014 as an early investor. The investment has been used for product development and commercial growth in recent years. Holland Capital is experienced in supporting innovative radiology solutions. This is the investor’s second exit in the field of medical imaging, following the acquisition of Quantib, a leading radiology artificial intelligence (“AI”) company, by RadNet Inc earlier this year.
Jan-Frens van Giessel, Partner Holland Capital : “We are proud that we have been able to assist Sigmascreening in the past 8 years. Sigmascreening’s pressure sensitive breast compression reduces extreme pain during mammography and improves detection of breast cancer. It is great to see that this important healthcare innovation will become available for women worldwide with the acquisition of Teledyne DALSA.”
About Teledyne DALSA
Teledyne DALSA provides state-of-the-art image sensing, capture and processing solutions to medical, dental, and scientific equipment manufacturers. Building on more than 30 years of proven capability and innovation, our highly skilled team of imaging specialists adds value with their continued focus on leading-edge product design. Our manufacturing processes are tailored to comply with the stringent quality, reliability, and traceability requirements of the medical and scientific X-ray community.
About Sigmascreening
Sigmascreening B.V. is a medical device company focusing on the development of new innovative products in the area of digital mammography and breast cancer screening. Sigmascreening was established as a spin-off company from the Amsterdam UMC.
About Holland Capital
Over the past 40 years, Holland Capital has responsibly and successfully invested in over more than 150 SME-companies. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital’s experienced and committed investment team understand entrepreneurship. They aim to establish an open, sustainable, and professional relationship with the companies they invest in, with the common goal of achieving growth. Holland Capital is backed by a broad network of successful Healthcare and Technology entrepreneurs.
1 quote is based on this scientific article: https://academic.oup.com/jbi/advance-article/doi/10.1093/jbi/wbaa070/5902745
Meet Emixa, your partner for digital transformation
Amsterdam, 9th of January 2023 – After a period of thorough preparation and refinement, the moment has arrived: our new consortium for digital transformation services launches its name: Emixa, accompanied by a new website and corporate identity. With Emixa, our...
Holland Capital wint voor 3e keer op rij M&A Award
Amsterdam, 16 december 2022 – Holland Capital wint voor het derde jaar op rij de M&A Award in de categorie Best Venture & Growth Capital Provider. Dit jaar was de investeerder twee maal genomineerd: ◾ Best Venture & Growth Capital Provider ◾ Best Small...
Holland Capital investeert in Cuccibu en QSN
Amsterdam, 2 december 2022 – Holland Capital investeert in Cuccibu en QSN, twee gerenommeerde spelers op het vlak van risicomanagement met een focus op Privacy en Security consultancy. De investering van Holland Capital zorgt er voor dat de ambitieuze groeiambities...
AMP groep en 2MC bundelen krachten
Amsterdam/Houten, 14 november 2022 – Onze deelneming AMP Groep bundelt haar krachten met medisch logistiek bedrijf 2MC. Door de krachtenbundeling, die mede mogelijk wordt gemaakt door Holland Capital, breidt de organisatie haar positie in de medische logistieke...
Defibrion neemt DefibSolutions over en breidt haar activiteiten uit
Amsterdam, 1 november 2022 – Onze deelneming Defibrion neemt DefibSolutions over, een groothandel in AED’s en reanimatie artikelen. Met de krachtenbundeling versterkt Defibrion haar positie binnen de markt van AED’s en aanpalende producten en diensten op het gebied...
Channext haalt €4,5M Series A financiering op
Utrecht, 27 september 2022 - Partner marketing platform Channext haalt €4,5 miljoen financiering op. De Series A ronde wordt geleid door Holland Capital, die samen met het Graduate Entrepreneur Fund en huidige investeerders participeren. Met de investering wil...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 311 94 11
Düsseldorf
Inselstraße 34
40479 Düsseldorf
+49 (0) 211 43 63 69 01
Contact
info@hollandcapital.nl





